Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

British Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 663-669

  Volm, M ^a   Rittgen, W ^a   Drings, P ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Chest Hospital   (Germany)

Author keywords

Cyclin A; ERBB 1; FOS; Immunohistochemistry; JUN; MYC; Prognosis; Squamous cell lung carcinoma; Survival; VEGF

Indexed keywords

CYCLIN A; VASCULOTROPIN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; ONCOGENE C FOS; ONCOGENE C JUN; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

EID: 0031963988     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.106     Document Type: Article

References (20)

1. Auwerx J and Sassone-Corsi P (1991) IP-1: a dominant inhibitor of FOS/JUN whose activity is modulated by phosphorylation. Cell 64: 983-993
2. Byar DR (1982) Analysis of survival data. Cox and Weibull models with covariates. In Statistics in Medical Research, Methods and Issues with Application in Cancer Research, Mike V and Stanley KE (eds), pp. 365-401. J Wiley: New York
3. Carney WP ( 1991) Oncogenes and non-oncogene related human tumor antigens. Cancer J 4: 156-161
4. Carr DT and Mountain CF ( 1977) Staging lung cancer. In Lung Cancer. Clinical Diagnosis and Treatment, Strauss MJ (ed.), pp. 151-161. Grune & Stratton: New York
5. Cordon-Cardo C (1995) Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia (review). Am J Path 147: 545-560
6. Dutta A, Chandra R, Leiter L and Lester S (1995) Cyclins as markers of tumor proliferation: Immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA 92: 5386-5390
7. Ferrara N, Houck K, Jakeman L and Leung DW (1992) Molecular and biological properties of the vascular endothelial-growth-factor family of proteins. Endocrine Rev 13: 8-32
8. Fleiss JL (1973) Statistical Methods for Rates and Proportion. J Wiley: New York
9. Kalbfleisch I and Prentice L (1980) Analysis of Failure Time Data. J Wiley: New York
10. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang S-M, Ogawa M, Sawada T and Sowa M (1996) Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77: 858-863
11. Moolenaar WH, Rob JA, Tertoolen LGJ and de Laat SW (1986) The epidermal growth factor induced signal in A 431 cells. J Biol Chem 261: 279-284
12. Paterlini P, Flejou JF, de Mitri MS, Pisi E, Franco D and Brechot C (1995) Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with low cytometric parameters. J Hepatol 23: 47-52
13. Sassone-Corsi P, Lamph WW, Kamps M and Verma IM (1988) FOS-associated cellular p39 is related to nuclear transcription factor AP-1. Cell 54: 553-563
14. Spandidos DA, Zakinthinos S, Petraki C, Sotsiou F, Yiagnisis M, Dimopoulos AM, Roussos G and Field JK (1990) Expression of ras p21 and myc p62 oncoproteins in small cell and non-small cell carcinomas of the lung. Anticancer Res 10: 1105-1114
15. Toi M, Hoshina S, Takayanagi T and Tominaga T (1994) Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85: 1045-1049
16. Volm M, Bak M, Efferth T, Lathan B and Mattern J (1988) Immunocytochemical detection of a resistance-associated glycoprotein in tissue culture cells, ascites tumors and human tumor xenografts by Mab 265/F4. Anticancer Res 8: 531-536
17. Volm M, Mattern J and Samsel B (1993) Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein, and glutathione S-transferase-π in human lung tumors. Cancer 71: 3181-3187
18. Volm M, van Kaick G and Mattern J (1994) Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metast 12: 329-334
19. Weidner N (1995) Intratumorous microvessel density as a prognostic factor in cancer. Am J Path 147: 9-19
20. World Health Organization (1981) Histological typing of lung tumors. Tumori 6: 253-272